In Response to Continuation of Lorlatinib Beyond Progressive Disease.
作者信息
Ignatius Ou Sai-Hong
机构信息
Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California.
出版信息
J Thorac Oncol. 2022 Sep;17(9):e86-e88. doi: 10.1016/j.jtho.2022.07.1149.
PMID:36031299
Abstract
摘要
相似文献
1
In Response to Continuation of Lorlatinib Beyond Progressive Disease.针对劳拉替尼在疾病进展后继续使用的情况。
J Thorac Oncol. 2022 Sep;17(9):e86-e88. doi: 10.1016/j.jtho.2022.07.1149.
2
Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease.ALK 阳性 NSCLC 疾病进展后继续使用洛拉替尼治疗。
J Thorac Oncol. 2022 Apr;17(4):568-577. doi: 10.1016/j.jtho.2021.12.011. Epub 2022 Jan 10.
3
A case study on severe psychiatric symptoms induced by lorlatinib.一例由劳拉替尼诱发的严重精神症状的病例研究。
Psychooncology. 2024 Jan;33(1):e6283. doi: 10.1002/pon.6283.
4
Podcast on the Management of Adverse Events Associated with Lorlatinib.关于劳拉替尼相关不良事件管理的播客。
Adv Ther. 2022 Apr;39(4):1447-1456. doi: 10.1007/s12325-022-02050-3. Epub 2022 Feb 11.
5
Lorlatinib in ROS1-positive NSCLC.洛拉替尼用于ROS1阳性非小细胞肺癌
Nat Rev Clin Oncol. 2020 Jan;17(1):7. doi: 10.1038/s41571-019-0301-6.
6
Lorlatinib-Associated Acute Respiratory Distress Syndrome.
Am J Ther. 2020 Nov/Dec;27(6):e698-e699. doi: 10.1097/MJT.0000000000001056.
7
Continuation of Lorlatinib May Bring Benefits to ALK-Positive NSCLC Beyond Progressive Disease; More Things Should Be Considered.劳拉替尼持续使用可能为ALK阳性非小细胞肺癌带来疾病进展后的益处；更多因素应予以考虑。
J Thorac Oncol. 2022 Sep;17(9):e85-e86. doi: 10.1016/j.jtho.2022.01.020.
8
Lorlatinib Exposed: A Far From Optimal Dose.洛拉替尼暴露：远非最佳剂量。
Clin Pharmacol Ther. 2022 Jun;111(6):1195-1196. doi: 10.1002/cpt.2579. Epub 2022 Apr 8.
9
Lorlatinib as a treatment for ALK-positive lung cancer.洛拉替尼治疗间变性淋巴瘤激酶阳性肺癌。
Future Oncol. 2022 Aug;18(24):2745-2766. doi: 10.2217/fon-2022-0184. Epub 2022 Jul 5.
10
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer.洛拉替尼在既往治疗的 ALK 阳性非小细胞肺癌患者中的脑渗透：CNS 和非 CNS 进展的累积发生率与洛拉替尼相关。
Target Oncol. 2020 Feb;15(1):55-65. doi: 10.1007/s11523-020-00702-4.
Zotero 插件